Results of a Phase II Trial of Brentuximab Vedotin for CD30(+) Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis

PURPOSE: Brentuximab vedotin, a monoclonal antibody (cAC10) conjugated to monomethyl auristatin E, targets CD30(+) receptors. This phase II open-label trial was conducted to evaluate safety and efficacy in CD30(+) cutaneous T-cell lymphomas. PATIENTS AND METHODS: Forty-eight patients with CD30(+) ly...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Clin Oncol
Main Authors: Duvic, Madeleine, Tetzlaff, Michael T., Gangar, Pamela, Clos, Audra L., Sui, Dawen, Talpur, Rakhshandra
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2015
Teme:
ORIGINAL REPORTS
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4737859/
https://ncbi.nlm.nih.gov/pubmed/26261247
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.60.3787
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki